We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals
VRCA

34 hedge funds and large institutions have $10.6M invested in Verrica Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

23.45% more ownership

Funds ownership: 2.69% → 26.15% (+23%)

21% less capital invested

Capital invested by funds: $13.4M → $10.6M (-$2.86M)

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

41% less funds holding

Funds holding: 58 → 34 (-24)

80% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 30

Holders
34
Holders Change
-24
Holders Change %
-41.38%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
11
Reduced
16
Closed
30
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
+$1.69M
2
UBS Group
UBS Group
Switzerland
+$207K
3
Renaissance Technologies
Renaissance Technologies
New York
+$123K
4
Morgan Stanley
Morgan Stanley
New York
+$115K
5
BCM
Bridgeway Capital Management
Texas
+$72.4K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.5M
2
Millennium Management
Millennium Management
New York
-$113K
3
YIH
Y-Intercept (HK)
Hong Kong
-$99.1K
4
Goldman Sachs
Goldman Sachs
New York
-$92.9K
5
BCM
BML Capital Management
Indiana
-$92.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$310 -$2.06K -342 -83%
Osaic Holdings
27
Osaic Holdings
Arizona
$301 +$3.08K +511 +896%
Optiver Holding
28
Optiver Holding
Netherlands
$134 +$187 +31 New
AAP
29
Arax Advisory Partners
Colorado
$38 +$54 +9 New
Group One Trading
30
Group One Trading
Illinois
$13 +$6 +1 +50%
MCM
31
MAI Capital Management
Ohio
$9 +$12 +2 New
Barclays
32
Barclays
United Kingdom
$4 -$6 -1 -50%
YIH
33
Y-Intercept (HK)
Hong Kong
– -$99.1K -18,696 Closed
Goldman Sachs
34
Goldman Sachs
New York
– -$92.9K -17,528 Closed
BCM
35
BML Capital Management
Indiana
– -$92.6K -17,465 Closed
Marshall Wace
36
Marshall Wace
United Kingdom
– -$65.7K -12,395 Closed
Two Sigma Investments
37
Two Sigma Investments
New York
– -$46.3K -8,729 Closed
SW
38
SteelPeak Wealth
California
– -$40.3K -7,600 Closed
BMO
39
Beck Mack & Oliver
New York
– -$37.1K -7,000 Closed
Citadel Advisors
40
Citadel Advisors
Florida
– -$36.4K -6,866 Closed
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
– -$35.3K -6,659 Closed
MMA
42
Miracle Mile Advisors
California
– -$31.7K -5,977 Closed
Qube Research & Technologies (QRT)
43
Qube Research & Technologies (QRT)
United Kingdom
– -$28.1K -5,296 Closed
AQR Capital Management
44
AQR Capital Management
Connecticut
– -$26.6K -5,027 Closed
Jane Street
45
Jane Street
New York
– -$20.3K -3,833 Closed
SFI
46
SPC Financial Inc
Maryland
– -$15.9K -3,000 Closed
DTL
47
Dynamic Technology Lab
Singapore
– -$11K -2,030 Closed
Creative Planning
48
Creative Planning
Kansas
– -$10.1K -1,908 Closed
PAS
49
Point72 Asia (Singapore)
Singapore
– -$7.27K -1,372 Closed
Wealth Enhancement Advisory Services
50
Wealth Enhancement Advisory Services
Minnesota
– -$8.17K -1,157 Closed
1
2
3

VRCA Hedge Fund Activity: Q3 2025 in Review

34 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2025, worth a combined $10.6M — down 21% from $13.4M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of VRCA and 6 opened new positions — a net loss of 24 holders — while 16 trimmed existing stakes and 11 added.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $1.69M. The largest seller was Armistice Capital, cutting an estimated $1.5M.

  • 34 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2025, down from 58 in Q2 2025.
  • Funds reported $10.6M of Verrica Pharmaceuticals stock for Q3 2025, down 21% quarter-over-quarter.
  • 6 funds opened new Verrica Pharmaceuticals positions in Q3 2025 and 30 closed out, a net change of -24 holders.
  • The largest Verrica Pharmaceuticals buyer in Q3 2025 was Boothbay Fund Management, an estimated $1.69M added.
  • The largest Verrica Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $1.5M sold.

Based on aggregated 13F filings for Q3 2025.